Do analysts prefer CPIX or CGC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Does the media favor CPIX or CGC?

In the previous week, Canopy Growth had 14 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 16 mentions for Canopy Growth and 2 mentions for Cumberland Pharmaceuticals. Canopy Growth's average media sentiment score of 0.93 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Canopy Growth 10 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CPIX or TTRX?

Turn Therapeutics has a consensus price target of $9.00, suggesting a potential downside of 32.48%. Given Turn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turn Therapeutics is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Turn Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.50

Does the media favor CPIX or TTRX?

In the previous week, Turn Therapeutics had 1 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 3 mentions for Turn Therapeutics and 2 mentions for Cumberland Pharmaceuticals. Turn Therapeutics' average media sentiment score of 0.41 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Turn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CPIX or AVIR?

Atea Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 36.45%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atea Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Do analysts rate RLMD or CPIX?

Relmada Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 233.33%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Relmada Therapeutics is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer RLMD or CPIX?

In the previous week, Relmada Therapeutics and Relmada Therapeutics both had 2 articles in the media. Relmada Therapeutics' average media sentiment score of 1.79 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SPRY or CPIX?

ARS Pharmaceuticals currently has a consensus target price of $25.00, indicating a potential upside of 514.25%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe ARS Pharmaceuticals is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor SPRY or CPIX?

In the previous week, ARS Pharmaceuticals had 20 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 22 mentions for ARS Pharmaceuticals and 2 mentions for Cumberland Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.11 beat Cumberland Pharmaceuticals' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 20 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cumberland Pharmaceuticals (CPIX) Competitors

$7.39 -0.12 (-1.60%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$7.42 +0.03 (+0.34%)

As of 10/2/2026 04:10 PM Eastern

Compare

CPIX vs. CGC, TTRX, AVIR, RLMD, and SPRY

Should you buy Cumberland Pharmaceuticals stock or one of its competitors? Cumberland Pharmaceuticals's main competitors and comparable companies include Canopy Growth (CGC), Turn Therapeutics (TTRX), Atea Pharmaceuticals (AVIR), Relmada Therapeutics (RLMD), and ARS Pharmaceuticals (SPRY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cumberland Pharmaceuticals compare to Canopy Growth?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Cumberland Pharmaceuticals has a beta of 0.06, indicating that its share price is 94% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Cumberland Pharmaceuticals has higher earnings, but lower revenue than Canopy Growth. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.49	-$2.84M	-$0.71	N/A
Canopy Growth	$251.01M	1.57	-$190.29M	-$0.45	N/A

In the previous week, Canopy Growth had 14 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 16 mentions for Canopy Growth and 2 mentions for Cumberland Pharmaceuticals. Canopy Growth's average media sentiment score of 0.93 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Canopy Growth	10 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 0.4% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cumberland Pharmaceuticals has a net margin of -34.40% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
Canopy Growth	-65.33%	-21.91%	-14.34%

Summary

Canopy Growth beats Cumberland Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Turn Therapeutics?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

In the previous week, Turn Therapeutics had 1 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 3 mentions for Turn Therapeutics and 2 mentions for Cumberland Pharmaceuticals. Turn Therapeutics' average media sentiment score of 0.41 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Turn Therapeutics has a consensus price target of $9.00, suggesting a potential downside of 32.48%. Given Turn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turn Therapeutics is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.50

Turn Therapeutics has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
Turn Therapeutics	N/A	-230.84%	-53.19%

Cumberland Pharmaceuticals has higher revenue and earnings than Turn Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than Cumberland Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.49	-$2.84M	-$0.71	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Turn Therapeutics beats Cumberland Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Atea Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

Cumberland Pharmaceuticals has higher revenue and earnings than Atea Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.49	-$2.84M	-$0.71	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

Atea Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 36.45%. Given Atea Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Cumberland Pharmaceuticals had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 2 mentions for Cumberland Pharmaceuticals and 0 mentions for Atea Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.00 equaled Atea Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Cumberland Pharmaceuticals	Neutral
Atea Pharmaceuticals	Neutral

Cumberland Pharmaceuticals has a beta of 0.06, indicating that its share price is 94% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Atea Pharmaceuticals has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Cumberland Pharmaceuticals and Atea Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Relmada Therapeutics has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-47.52%	-43.97%
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%

Relmada Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 233.33%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Relmada Therapeutics is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Relmada Therapeutics and Relmada Therapeutics both had 2 articles in the media. Relmada Therapeutics' average media sentiment score of 1.79 beat Cumberland Pharmaceuticals' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Relmada Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market.

Cumberland Pharmaceuticals has higher revenue and earnings than Relmada Therapeutics. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
Cumberland Pharmaceuticals	$44.52M	2.49	-$2.84M	-$0.71	N/A

Summary

Relmada Therapeutics beats Cumberland Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Cumberland Pharmaceuticals has a net margin of -34.40% compared to ARS Pharmaceuticals' net margin of -184.24%. Cumberland Pharmaceuticals' return on equity of -28.81% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ARS Pharmaceuticals has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.06, indicating that its share price is 94% less volatile than the broader market.

In the previous week, ARS Pharmaceuticals had 20 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 22 mentions for ARS Pharmaceuticals and 2 mentions for Cumberland Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.11 beat Cumberland Pharmaceuticals' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ARS Pharmaceuticals currently has a consensus target price of $25.00, indicating a potential upside of 514.25%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe ARS Pharmaceuticals is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cumberland Pharmaceuticals has lower revenue, but higher earnings than ARS Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	4.80	-$171.30M	-$2.18	N/A
Cumberland Pharmaceuticals	$44.52M	2.49	-$2.84M	-$0.71	N/A

Summary

ARS Pharmaceuticals beats Cumberland Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Cumberland Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPIX vs. The Competition

Export

Metric	Cumberland Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$112.52M	$12.24B	$7.14B	$13.17B
Dividend Yield	N/A	2.64%	2.53%	16.78%
P/E Ratio	-10.41	799.70	275.68	26.04
Price / Sales	2.49	842.26	658.29	101.16
Price / Cash	20.48	82.26	77.60	51.75
Price / Book	4.51	10.46	10.93	6.31
Net Income	-$2.84M	$2.84B	$3.51B	$362.16M
7 Day Performance	-2.89%	-1.57%	-2.00%	-1.66%
1 Month Performance	9.48%	-5.67%	-6.15%	-4.50%
1 Year Performance	136.10%	-4.73%	7.44%	2.06%

Cumberland Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPIX Cumberland Pharmaceuticals	0.2586 of 5 stars	$7.39 -1.6%	N/A	+128.1%	$112.52M	$44.52M	N/A	93	News Coverage
CGC Canopy Growth	0.9484 of 5 stars	$0.96 -0.8%	N/A	-35.6%	$430.43M	$251.01M	N/A	1,128
TTRX Turn Therapeutics	1.8394 of 5 stars	$14.32 -6.4%	$9.00 -37.1%	N/A	$430.02M	N/A	N/A	2
AVIR Atea Pharmaceuticals	1.9078 of 5 stars	$5.36 -5.0%	$7.00 +30.6%	+81.9%	$427.36M	N/A	N/A	55
RLMD Relmada Therapeutics	2.6114 of 5 stars	$3.92 -7.7%	$12.00 +206.5%	+35.3%	$416.55M	N/A	N/A	17	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CPIX) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cumberland Pharmaceuticals (CPIX) Competitors

CPIX vs. CGC, TTRX, AVIR, RLMD, and SPRY

How does Cumberland Pharmaceuticals compare to Canopy Growth?

Summary

How does Cumberland Pharmaceuticals compare to Turn Therapeutics?

Summary

How does Cumberland Pharmaceuticals compare to Atea Pharmaceuticals?

Summary

How does Cumberland Pharmaceuticals compare to Relmada Therapeutics?

Summary

How does Cumberland Pharmaceuticals compare to ARS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX vs. The Competition

Cumberland Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cumberland Pharmaceuticals (CPIX) Competitors

CPIX vs. CGC, TTRX, AVIR, RLMD, and SPRY

How does Cumberland Pharmaceuticals compare to Canopy Growth?

Which has more volatility and risk, CPIX or CGC?

Which has stronger valuation & earnings, CPIX or CGC?

Does the media favor CPIX or CGC?

Do analysts prefer CPIX or CGC?

Do insiders and institutionals believe in CPIX or CGC?

Is CPIX or CGC more profitable?

Summary

How does Cumberland Pharmaceuticals compare to Turn Therapeutics?

Does the media favor CPIX or TTRX?

Do analysts recommend CPIX or TTRX?

Is CPIX or TTRX more profitable?

Which has preferable earnings & valuation, CPIX or TTRX?

Do insiders & institutionals have more ownership in CPIX or TTRX?

Summary

How does Cumberland Pharmaceuticals compare to Atea Pharmaceuticals?

Which has higher valuation and earnings, CPIX or AVIR?

Do analysts prefer CPIX or AVIR?

Does the media favor CPIX or AVIR?

Which has more risk & volatility, CPIX or AVIR?

Is CPIX or AVIR more profitable?

Do institutionals and insiders believe in CPIX or AVIR?

Summary

How does Cumberland Pharmaceuticals compare to Relmada Therapeutics?

Is RLMD or CPIX more profitable?

Do analysts rate RLMD or CPIX?

Does the media prefer RLMD or CPIX?

Do insiders and institutionals believe in RLMD or CPIX?

Which has more volatility and risk, RLMD or CPIX?

Which has preferable earnings & valuation, RLMD or CPIX?

Summary

How does Cumberland Pharmaceuticals compare to ARS Pharmaceuticals?

Is SPRY or CPIX more profitable?

Do insiders and institutionals have more ownership in SPRY or CPIX?

Which has more risk & volatility, SPRY or CPIX?

Does the media favor SPRY or CPIX?

Do analysts rate SPRY or CPIX?

Which has higher valuation and earnings, SPRY or CPIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX vs. The Competition

Cumberland Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools